Prolacta Announces the First Premature Infant Formula Made from Human Milk

-- “Ready-to-Feed” Products Will be the First Preterm Formula Made from Human Milk --

City of Industry, CA. Feb. 20, 2014 – Prolacta Bioscience announces a new line of “ready to feed” premature infant formula products for preemies in the neonatal intensive care unit (NICU). The products, Prolact RTF™ (RTF), will be a pre-mixed premature infant formula made from human milk that will provide an easy and convenient way to provide 100% human milk-based fortified nutrition when a mother’s own milk is unavailable. The RTF products will provide standardized caloric content of 24, 26, or 28 calories, depending upon the neonatologist's prescription. This is the first formula for premature infants made from human milk as opposed to cow milk. The products are being announced at the NEO Conference for Neonatology, which is being held February 20-23, 2014 in Orlando, FL.

Prolacta is the only company to make a full range of standardized nutritional products for premature infants from human milk, as opposed to cow milk, and this new line of products will further enable Prolacta to meet the needs of hospitals that wish to provide exclusive human milk nutrition in their NICUs. This is particularly important when mom’s milk is unavailable because Prolacta’s fortifier must be mixed with mom’s milk or donor milk in order to provide a 100% human milk diet to the premature infant.

These “ready-to-feed” premature infant formula products will provide all of the benefits of an exclusive human milk diet for extremely premature infants. Several studies have pointed to these benefits including the reduced risk of premature infants developing the often-fatal intestinal disease necrotizing enterocolitis (NEC). The most recent study was released this past August and demonstrated that extremely premature infants who are fed an exclusive human milk diet instead of preterm formula have a significantly lower incidence of surgery associated with NEC and require fewer days of intravenous feedings through total
parenteral nutrition (TPN). Additionally, the 2012 policy statement issued by the American Academy of Pediatrics points to the same benefits of human milk, and took a step further by recommending that all preterm infants receive human milk, whether their mother’s own milk or, if mother’s milk was unavailable, pasteurized donor breast milk.

Prolacta is setting the new standard of safety and quality in human milk processing, with a pharmaceutical grade manufacturing facility that is the first and only of its kind worldwide. Additionally, Prolacta is the only organization that includes a safety combination of DNA matching of mom to milk, testing the milk for drugs and other contaminants, as well as for HIV-1, HCV, and HBV through PCR testing to ensure the highest-quality available human milk products to feed the sickest infants in hospital NICUs. Prolacta’s advanced technology provides for an unmatched margin of safety to protect preterm infants. Please join in on the conversation about Prolacta.

About Prolacta Bioscience
Prolacta Bioscience, Inc., www.prolacta.com, is a life science company dedicated to improving quality of life by Advancing the Science of Human Milk®. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in NICU. It is the first and only company to provide a commercially available human milk fortifier made from 100% human milk, Prolact+ H²MF. Prolacta operates a pharmaceutical grade processing plant and has designed and patented processes that enable them to make their one-of-a-kind products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable premature babies through world-class research and innovative products.

###